RELISTOR 20 MG
METHYLNALTREXONE BROMIDE : 20 MG · DIN 02308215 · SALIX PHARMACEUTICALS INC
Health Canada status: MARKETED
What is RELISTOR?
RELISTOR 20 MG contains METHYLNALTREXONE BROMIDE : 20 MG. It is listed in the Health Canada Drug Product Database under DIN 02308215, held by SALIX PHARMACEUTICALS INC, supplied as SOLUTION for SUBCUTANEOUS administration. Health Canada currently lists it as marketed, status dated 18-Jan-2021. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is RELISTOR used for?
Treatment of opioid-induced constipation in patients with advanced illness, receiving palliative care, when response to laxatives has been insufficient. Used as an adjunct therapy.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02308215 |
|---|---|
| Brand name | RELISTOR |
| Generic / active ingredient | METHYLNALTREXONE BROMIDE : 20 MG |
| Manufacturer | SALIX PHARMACEUTICALS INC |
| Strength | 20 MG |
| Dosage form | SOLUTION |
| Route of administration | SUBCUTANEOUS |
| Schedule | Prescription |
| ATC code | A06AH01 METHYLNALTREXONE BROMIDE |
| AHFS class | 56:92.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 18-Jan-2021 |
| Original market date | 2008-05-07 00:00:00 |
How is it administered?
Subcutaneous injection. Advanced illness: 8 mg (weight 38 to <62 kg) or 12 mg (62 to 114 kg). Patients outside these ranges should be dosed at 0.15 mg/kg. Administer as an adjunct therapy.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text summary (Table of Contents lists page 25), but typically 15-30°C. (Note: Text provided ends before specific storage temp).
How is it supplied?
Vial (12 mg/0.6mL); Vial plus syringe with retractable needle; Pre-Filled Syringes (8 mg/0.4mL & 12 mg/0.6 mL).
Contraindications
Hypersensitivity to any components; known or suspected mechanical gastrointestinal obstruction or acute surgical abdomen.
Warnings and precautions
Risk of GI perforation in patients with reduced structural integrity of the GI wall. Discontinue if severe/persistent diarrhea or worsening abdominal symptoms occur. Caution with GI lesions.
What can be used instead?
Other Canadian products sharing ATC code A06AH01 METHYLNALTREXONE BROMIDE. 1 of 3 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| RELISTOR | 20 MG | SOLUTION | SALIX PHARMACEUTICALS INC | APPROVED | DIN 02356481 |
| RELISTOR | 20 MG | SOLUTION | SALIX PHARMACEUTICALS INC | APPROVED | DIN 02356503 |
Who else supplies METHYLNALTREXONE BROMIDE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. METHYLNALTREXONE BROMIDE appears in 9 registered pack listings across 5 markets, published on 5 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.